Positions

Selected Publications

Academic Article

Year Title Altmetric
2023 Early time-restricted eating affects weight, metabolic health, mood, and sleep in adherent completers: A secondary analysisObesity.  31:96-107. 2023
2023 Impact of early time-restricted eating on diet quality, meal frequency, appetite, and eating behaviors: A randomized trialObesity.  31:127-138. 2023
2022 Hormone therapy and fractures in postmenopausal womenAIDS.  36:1683-1688. 2022
2022 Effectiveness of Early Time-Restricted Eating for Weight Loss, Fat Loss, and Cardiometabolic Health in Adults with Obesity: A Randomized Clinical TrialJAMA Internal Medicine.  182:953-962. 2022
2022 Understanding Physicians’ Perceptions of Patient-Identified Barriers to Osteoporosis Medication Initiation: A Cognitive Mapping ApproachRisk Management and Healthcare Policy.  15:1293-1302. 2022
2018 Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical TrialJournal of Bone and Mineral Research.  33:763-772. 2018
2017 Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot studyOsteoporosis International.  28:2495-2503. 2017
2017 Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study (Osteoporosis International, (2017), 28, 8, (2495-2503), 10.1007/s00198-017-4073-5)Osteoporosis International.  28:2505. 2017
2016 A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention materialContemporary Clinical Trials Communications.  4:14-24. 2016
2016 Understanding practice-based research participation: The differing motivations of engaged vs. non-engaged clinicians in pragmatic clinical trialsContemporary Clinical Trials Communications.  4:136-140. 2016
2016 A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis studyContemporary Clinical Trials Communications.  3:32-38. 2016
2016 Medical therapy for osteoporosis and approaches to improving adherenceJCOM.  23:329-336. 2016
2016 Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patientsCurrent Opinion in HIV and AIDS.  11:351-357. 2016
2015 An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid usersJournal of Rheumatology.  42:1478-1483. 2015
2015 Fructosamine and hemoglobin a1c correlations in HIV-infected adults in routine clinical care: Impact of anemia and albumin levelsAIDS Research and Treatment.  2015. 2015
2014 Bone alterations associated with HIVCurrent HIV/AIDS Reports.  11:233-240. 2014
2014 Molecular mechanism of thiazolidinedione-mediated inhibitory effects on osteoclastogenesisPLoS One.  9. 2014
2014 Effect of self-referral on bone mineral density testing and osteoporosis treatmentMedical Care.  52:743-750. 2014
2014 HIV-Related Metabolic Comorbidities in the Current ART EraInfectious Disease Clinics of North America.  28:457-476. 2014
2013 Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoidsCurrent Opinion in Endocrinology, Diabetes and Obesity.  20:510-516. 2013
2013 Prevention and treatment of bone changes associated with exposure to glucocorticoidsCurrent Osteoporosis Reports.  11:341-347. 2013
2013 Challenges in defining quality of care for glucocorticoid-induced osteoporosis: Defending good against perfectJournal of Rheumatology.  40:1640-1642. 2013
2013 Study design considerations for a large simple trial of bisphosphonatesCurrent Opinion in Rheumatology.  25:517-523. 2013
2013 Osteoporosis Diagnosis and Medical TreatmentOrthopedic Clinics of North America.  44:125-135. 2013
2013 Low hemoglobin levels and recurrent falls in U.S. Men and Women: Prospective findings from the REasons for Geographic and racial differences in stroke (REGARDS) cohortAmerican Journal of the Medical Sciences.  345:446-454. 2013
2013 Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: Feasibility, satisfaction, and sample sizePatient Preference and Adherence.  7:517-523. 2013
2012 A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal womenJournal of Bone and Mineral Research.  27:2603-2610. 2012
2012 Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United StatesContemporary Clinical Trials.  33:1211-1216. 2012
2011 Minor, Major, Low-Trauma, and high-trauma fractures: What are the subsequent fracture risks and how do they vary?Current Osteoporosis Reports.  9:122-128. 2011
2011 Which fractures are most attributable to osteoporosis?Journal of Clinical Epidemiology.  64:46-53. 2011
2010 Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medicationPLoS One.  5:1-8. 2010
2010 Bone changes and fracture risk in individuals infected with HIVCurrent Rheumatology Reports.  12:163-169. 2010
2010 Is withholding osteoporosis medication after fracture sometimes rational? A Comparison of the risk for second fracture versus death 2010
2009 "pathologic" fractures: Should these be included in epidemiologic studies of osteoporotic fractures?Osteoporosis International.  20:1969-1972. 2009
2009 Adherence to osteoporosis treatments: Room for improvementCurrent Opinion in Rheumatology.  21:356-362. 2009
2009 Management of osteoporosis among home health and long-term care patients with a prior fractureSouthern Medical Journal.  102:397-404. 2009
2008 Improving quality of care in osteoporosis: Opportunities and challengesCurrent Rheumatology Reports.  10:123-130. 2008
2007 Challenges in defining and improving osteoporosis quality of careClinical and Experimental Rheumatology.  25. 2007

Chapter

Year Title Altmetric
2009 Osteoporosis.  393-404. 2009

Investigator On

  • A Phase IIa, Randomized, Double-Blind Placebo-Controlled, Dose Comparison, Multi-Centre Adaptive Design Clinical Trial to Evaluate The Immune Signature of The Treatment with The Imotope™ IMCY-0098 and its effect on the Preservation of Beta-Cell Function in Adult Patients with A Recent Onset Type 1 Diabetes  awarded by IMCYSE SA
  • A Study of the Genetic Causes of Latent Autoimmune Diabetes in Adults  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Cardiovascular Inflammation Reduction Trial (CIRT): A Randomized Double-Blind Placebo-Controlled, Event-Driven Trial of Weekly Low-Dose Methotrexate (LDM) in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients  awarded by Brigham and Women's Hospital
  • Diabetic Macular Edema Found by OCT Utilization at Non-Ophthalmic Diabetes Care Visits  awarded by Joslin Diabetes Center
  • Effectiveness of DiscontinuinG BisphosphonatEs Study (EDGE)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Establishment of a Comprehensive, Interdisciplinary Gender Health Clinic  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • Evaluating the Association Between Cardiometabolic Health Over the Lifespan and Vertebral Strength  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Implementation of Direct-to-Patient Telemedicine Healthcare Initiatives  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION
  • Improving Weight Loss Outcomes of Black Women using a Culturally-Relevant Stress-Management Enhanced Behavioral Weight Loss Intervention  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • NIAMS Multidiscipllinary Clinical Research Center  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • NIAMS Multidiscipllinary Clinical Research Center - Project 4  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Pilot Studies for the Active Comparator Osteoporosis Large Simple Trial (ATLAST)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by GI DYNAMICS, INC.
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by Janssen
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by PROLOR BIOTECH
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by BIODEL, INC.
  • Private Grant  awarded by ALEXION PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC.
  • Private Grant  awarded by CHIASMA, INC.
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by MILLENDO THERAPEUTICS
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by THERACOS SUB, LLC
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by KOWA
  • Private Grant  awarded by XERIS PHARMACEUTICALS
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by MEREO BIOPHARMA 3 LIMITED
  • Private Grant  awarded by IRONWOOD PHARMACEUTICALS, INC.
  • Private Grant  awarded by CHIASMA, INC.
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by GAN & LEE PHARMACEUTICAL
  • Private Grant  awarded by GAN & LEE PHARMACEUTICAL
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by XERIS PHARMACEUTICALS
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC.
  • Private Grant  awarded by ALLERGAN SALES, LLC
  • Private Grant  awarded by INTREXON T1D PARTNERS. LLC
  • Private Grant  awarded by ALLERGAN SALES, LLC
  • Private Grant  awarded by ALLERGAN SALES, LLC
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by CHIASMA, INC.
  • Private Grant  awarded by CORCEPT THERAPEUTICS, INC.
  • Private Grant  awarded by DOMPE S.P.A. ^
  • Private Grant  awarded by DOMPE S.P.A. ^
  • Private Grant  awarded by AMRYT PHARMA PLC
  • UAB Obesity Medicine Fellowship  awarded by OBESITY MEDICINE FELLOWSHIP COUNCIL
  • Education And Training

  • University of Arkansas Medical Center, Internship
  • University of Arkansas Medical Center, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine in Endocrinology, Diabetes and Metabolism Residency Program, University of Arkansas 2002
  • Full Name

  • Amy Warriner